On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the May 2024 CRG meeting. Actions in this consultation include:

  • Sunscreens for ACBS conditions – discontinued products to be removed from formulary and replaced with Anthelios SPF 50+ lotion (first choice) and Uvistat Suncream SPF 50 (alternative)
  • Remdesivir and tixagevimab plus cilgavimab – RED
  • Atogepant for treating migraine – Green (specialist advice)
  • Setmelanotide – RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 5th July 2024. To take part, visit the consultations page.